Unraveling the Differences between Gram-Positive and Gram-Negative Probiotics in Modulating Protective Immunity to Enteric Infections

Sukumar Kandasamy, Anastasia N. Vlasova, David D. Fischer, Kuldeep S. Chattha*, Lulu Shao*, Anand Kumar†, Stephanie N. Langel, Abdul Rauf, Huang-Chi Huang, Gireesh Rajashekara and Linda J. Saif*

Food Animal Health Research Program (FAHRP), Veterinary Preventive Medicine Department, The Ohio Agricultural Research and Development Center, The Ohio State University, Wooster, OH, USA

The role of intestinal microbiota and probiotics in prevention and treatment of infectious diseases, including diarrheal diseases in children and animal models, is increasingly recognized. Intestinal commensals play a major role in development of the immune system in neonates and in shaping host immune responses to pathogens. Lactobacilli spp. and *Escherichia coli* Nissle 1917 are two probiotics that are commonly used in children to treat various medical conditions including human rotavirus diarrhea and inflammatory bowel disease. Although the health benefits of probiotics have been confirmed, the specific effects of these established Gram-positive (G+) and Gram-negative (G−) probiotics in modulating immunity against pathogens and disease are largely undefined. In this review, we discuss the differences between G+ and G− probiotics/commensals in modulating the dynamics of selected infectious diseases and host immunity. These probiotics modulate the pathogenesis of infectious diseases and protective immunity against pathogens in a species- and strain-specific manner. Collectively, it appears that the selected G− probiotic is more effective than the various tested G+ probiotics in enhancing protective immunity against rotavirus in the gnotobiotic piglet model.

**Keywords**: rotavirus, probiotics, *Escherichia coli* Nissle, *Lactobacillus*, immunity, children, diarrhea, gnotobiotic piglet disease model

**INTRODUCTION**

Intestinal commensals constitute more than 1,000 species of bacteria. These commensals are involved in nutrient metabolism, development, and functioning of the gastrointestinal (GI) immune system and protection of the host from pathogens (1–3). Colonization of the GI tract is a gradual process in which *Escherichia coli* and other enterobacteria colonize the intestinal tract early after birth, followed by the subsequent establishment of anaerobes (4). The intestinal microbiota of children only becomes adult-like at 2–3 years of age (5). Perturbation of the intestinal microbiota, or dysbiosis, is associated with various diseases such as inflammatory bowel disease (6) and also affects the efficacy of various vaccines in children (7). Probiotics are widely used to restore gut homeostasis in various medical conditions in humans (8–10) and treat diarrheal diseases in children.
Diarrheal disease is one of the leading cause of deaths in children and it accounts for the death an estimated of 700,000 children annually worldwide (11). Specifically, rotavirus (RV) is a major cause of gastroenteritis in children worldwide. The protective efficacy of available RV vaccines is variable between regions and it is lowest in developing countries such as Southern Asia (50.0%) and sub-Saharan Africa (46.1%) (12). Additionally, lack of access to adequate health-care facilities to manage diarrhea is also associated with higher morbidity and mortality in children in low-income settings. Thus, enhancing vaccine efficacy, along with developing economical approaches to reduce the severity of RV diarrhea are effective strategies to ameliorate severe RV disease. Probiotics and intestinal commensals, crucial interacting partners of the gut immune system (13), are increasingly being considered for treatment of various enteric infections including human retrovirus (HRV) diarrhea (14), human norovirus gastroenteritis (15), antibiotic-associated diarrhea (16), and also to modulate protective antiviral immunity (17).

The beneficial effects of probiotics in reducing the severity of RV diarrhea and modulating viral immunity were observed in randomized clinical studies (18) and experimental studies in animal models (19) (Table 1). The Gram-positive (G+) Lactobacillus spp. were widely used to treat or prevent RV diarrhea in children. Specifically, prophylactic supplementation of Lactobacillus rhamnosus GG (LGG) to children significantly reduced the incidence of HRV disease (20). In our studies, gnotobiotic (Gn) piglets were used to study HRV pathogenesis due to their susceptibility to HRV infection and also the greater anatomic and physiological and immunological similarities between pigs and humans. Dual colonization of Gn piglets with G+ LGG and Bifidobacterium lactis Bb12 resulted in a significant reduction in both fecal HRV shedding titers and diarrhea severity (21). Further, Lactobacillus strains have significant effects in reducing diarrhea severity in children affected by enteric diseases (22).

The effectiveness of probiotics in preventing or treating a disease is dependent on several factors such as class or strains of probiotics, the dosage of probiotics, and heterogeneity of study subjects (40, 41). Several past studies showed strain-specific differences of probiotics in modulating host immune responses (42). Thus, comparative analysis of the health benefits of different classes of probiotics is essential to tailor an effective regimen of probiotic treatment for a disease condition. Specifically variations in microbe-associated molecular patterns between G+ and Gram-negative (G−) bacteria have been attributed to differential induction of innate immunity in a host (43, 44). However, limited studies have been conducted to decipher if differences exist between G+ and G− probiotics in modulating host responses to infectious diseases. In our recent studies (31, 32), we compared the beneficial effects of G+ and G− probiotics in modulating virulent HRV infection as well as host immunity. Specifically, LGG was selected as a G+ probiotic because of its well-documented effects in reducing the severity of RV diarrhea in children (24). For the G− probiotic, we selected Escherichia coli Nissile 1917 (EcN) due to its proven effects in attenuating inflammatory disorders and modulating immunity in humans (45). In this review, we focused on the comparisons of the health benefits of G+ and G− probiotics in modulating microbial infections and immunity.

### EFFECTS OF G+ VERSUS G− PROBIOTICS ON ENTERIC INFECTIONS AND DIARRHEA

Probiotics have been successfully used to prevent or treat enteric infections in children and animals (Table 1). One notable finding is the difference between G+ and G− probiotics in modulating host immunity against microbial diseases. In one study (31), the comparative efficacy of LGG and EcN probiotics in ameliorating HRV disease was assessed in Gn piglets. The EcN colonized piglets had reduced diarrhea severity and also lower mean peak virus shedding titers compared with LGG or uncolonized piglets post-virulent human RV (VirHRV) challenge (31, 32). Both EcN and LGG showed similar colonization patterns as indicated by comparable fecal shedding of each bacterium and also detection of similar levels of each probiotic bacteria in various sections of GI tract. Similarly, EcN supplementation to children with enteric infections resulted in reduced duration of diarrhea (26). Further, supplementation of EcN to infants for the first 5 days immediately after birth resulted in persistence of the probiotic for 6 months as indicated by fecal shedding of EcN (29). Similar to the higher beneficial effects of EcN than LGG on ameliorating HRV infections, higher protective effects against Salmonella were observed in EcN compared with Bifidobacterium choerinum-supplemented Gn piglets (30). The higher protective effect of EcN against Salmonella was associated with increased expression of ZO-1 and occludin in ileal epithelial cells and decreased inflammatory TNF-α cytokine levels in the EcN colonized Gn piglets (30). Consistent with these findings, higher TNF-α levels were induced by G+ commensals as compared with G− commensals using in vitro mononuclear cultures (43). EcN supplementation also attenuated lipopolysaccharides (LPS) or trinitrobenzene sulfonic acid-induced inflammatory conditions in a mouse model (46). In summary, the higher ability of G− compared with G+ probiotics in reducing the levels of inflammatory mediators during enteric infections may be major contributing factor in reducing diarrhea severity.

### G+ and G− Probiotic Impacts on Modulation of B Cell Responses

Microbial colonization of the GI tract has a significant effect on the maturation of neonatal immune system (47). Consistent with this observation, administration of EcN enhanced serum EcN-specific IgA antibody and polyclonal IgM antibody responses in infants as compared with placebo group (28). Also, mono EcN or dual EcN + LGG colonization significantly increased serum total IgA and IgG responses compared with LGG colonized or uncolonized piglets (31) (Figure 1). Similar to systemic immunoglobulin responses, EcN colonization resulted in higher small intestinal total IgA responses compared with LGG colonization in Gn pigs. Thus, EcN had more potent immunostimulatory effects than LGG in terms of inducing mucosal and systemic B cell responses. The underlying mechanism for differential induction of antibody responses by G+ and G− bacteria might be due to variation in IgA inducing factors such as IL-10 cytokine. In fact, G−, but not G+ probiotics, induced higher IL-10 responses in
### TABLE 1 | Effects of G+ and G− probiotics on diarrheal diseases and immunity in children and animal models.

| Gram-positive probiotic/commensal bacteria | Gram-negative probiotic/commensal bacteria | Humans/animal model/in vitro study | Indication | Conclusion(s)                                                                 | Reference |
|------------------------------------------|-------------------------------------------|-----------------------------------|------------|-------------------------------------------------------------------------------|-----------|
| *L. rhamnosus* GG (6 × 10^9 CFU/dose)    | None                                      | Children                          | Prophylaxis against diarrheal diseases | Significant reduction in incidence of HRV disease in LGG-supplemented group | (20)      |
| *L. rhamnosus* GG (10^{10–11} CFU)     | None                                      | Children                          | Effect of LGG on immune responses to HRV in children | LGG significantly enhanced RV-specific IgA antibody responses | (23)      |
| *L. rhamnosus* GG (10^{10} CFU)         | None                                      | Children                          | Treating diarrhea                        | Reduced duration of diarrhea                                         | (24)      |
| *Lactobacillus paracasei strain ST11* (10^{10} CFU) | None                                      | Children                          | Treating diarrhea                        | Reduced severity of non-rotavirus induced diarrhea but no effect on rotavirus diarrhea | (25)      |
| None                                    | *Escherichia coli* Nissle 1917 (EcN) (10^{8} CFU) | Children                          | Treat acute diarrhea in children         | Reduced duration of diarrhea by 2.3 days                              | (26)      |
| None                                    | EcN (5 × 10^{6} CFU)                      | Infants                           | To assess effects on total IgA responses in infants | Increased serum and stool IgA responses                               | (27)      |
| None                                    | EcN (10^{8} CFU)                         | Infants                           | Assess impact on cellular and humoral immunity in infants | Probiotic increased both cellular proliferative and serum total IgA responses | (28)      |
| None                                    | EcN (10^{8} CFU)                         | Infants                           | Prophylactic administration against bacterial pathogens | Significant reduction in bacterial pathogens in fecal samples         | (29)      |
| *Bifidobacterium choerinum* (5 × 10^{8} CFU/ml) | *EcN* (5 × 10^{8} CFU/ml)              | Gn piglets                        | Protection against *Salmonella enterica* serovar Typhimurium infection | EcN conferred higher protection against disease than *Bifidobacterium choerinum* | (30)      |
| *L. rhamnosus* GG (10^{8} CFU/ml)       | *EcN* (5 × 10^{8} CFU/ml)               | Gn piglets                        | Compare G+ and G− bacteria effect on HRV infection and immunity | EcN was more effective than LGG in ameliorating HRV disease and enhancing total IgA and NK cell responses | (31, 32) |
| *L. rhamnosus* GG (10^{8} CFU/ml), *Bifidobacterium lactis* Bb12 (10^{6} CFU/ml) | None                                      | Gn piglets                        | To study effects on HRV disease | Reduced fecal virus shedding and diarrhea severity in probiotic colonized piglets | (33)      |
| *Enterococcus faecium* NCIMB 10415 (4.2–4.3 × 10^{9}/g CFU) | None                                      | Sows and their offspring          | Effect on fecal shedding of enteric viruses | Reduced fecal shedding of rotavirus and increased rotavirus specific IgA responses. No effect on hepatitis E virus, encephalomyocarditis virus, and norovirus shedding in feces | (34)      |
| None                                    | EcN (10^{10} CFU/ml)                     | Pigs                              | To prevent enterotoxigenic *Escherichia coli* induced diarrhea | Ameliorated clinical signs of diarrhea                                | (35)      |
| None                                    | EcN (10^{6} CFU/ml)                      | Neonatal calf                     | Prevention and treatment of diarrhea     | Reduction in incidence of diarrheal diseases in prophylactic group. Ameliorated severity of diarrhea in calves with enteric diseases | (36)      |
| *Lactobacillus acidophilus* A9 (10^{8} CFU/ml) | *Escherichia coli* 13-7 (10^{8} CFU/ml) | Mice                              | Compare G+ and G− bacteria effect on cytokine responses in mice | E. coli 13-7 induced higher IL-12 cytokine compared to *L. acidophilus* A9 | (37)      |
| None                                    | EcN (1.5–2 × 10^{9} CFU)                | Mice                              | Assess impact on intestinal barrier function in acute dextran sodium sulfate-induced colitis | Strengthened intestinal barrier function                              | (38)      |
| *Lactobacillus casei* Shirota | EcN                                       | *In vitro*                        | Investigate effects on innate immunity   | Higher IL-10 and IL-12 induction by EcN than *L. casei* Shirota         | (39)      |
| *L. plantarum, L. rhamnosus, L. paracasei sp.* | *Escherichia coli* O6:K13:H1, *Escherichia coli* MS101 | *In vitro*                        | Compare G+ and G− bacteria effect on cytokine responses of monocytes | Lactobacilli-induced higher level of IL-12 | (20, 21, 22) |
prior studies (31, 48, 49). IL-10 is one of the cytokines that mediates the induction of IgA antibody responses at mucosal sites through enhancing antibody class switching (50). Differences in the microbe-associated molecular patterns between the probiotics might be a potential reason for the differential induction of IL-10 by G+ and G− bacteria. Indeed, both the LPS portion of EcN and whole EcN lysate were identified as potent inducers of IL-10 production in peripheral blood mononuclear cells (51). Further, induction of total IgA responses is at least partially mediated by IL-10 in vitro (31). These studies demonstrate that modulation of the cytokine milieu, such as enhanced IL-10 levels, might be a potential mechanism to account for the higher antibody responses observed in G− compared with G+ probiotics groups.

It is also well established that strain-dependent variations in immunomodulatory properties are observed within G+ probiotics (52). Thus, individual probiotic strains within G+ or G− probiotic classes may differ in modulating antibody responses. Consequently, screening of the beneficial effects of individual probiotics is essential to elucidate their impacts on antibody responses.

**Impact of Innate Immunity on IgA Responses to G+ versus G− Probiotics**

Innate immunity plays an integral role in priming the adaptive immune responses. Thus, probiotics may induce specific changes in innate immunity that may be involved in synergistically enhancing IgA responses. Dual colonization of a G− and G+ probiotic enhanced serum total IgA responses in Gn piglets compared with mono-colonization of the probiotics (31). Thus, G+ and G− bacteria synergistically enhanced the systemic total IgA responses. In fact, combinations of G+ and G− probiotics had additive effects on induction of maturation markers in DCs as well as levels of IL-10 cytokines (53). Thus, considering the known function of DCs in induction of IgA responses (54, 55), the positive effects of combinations of G+ and G− bacteria in modulating DCs may play a role in enhancing IgA responses. Additionally, a previous...
study (56) also showed that LPS, a TLR4 ligand, synergistically interacted with TLR1/2 ligands which in turn enhanced class-switch recombination in B cells. Thus, synergistic interactions of microbe-associated molecular patterns from G− and G+ probiotics might also play a role in enhancing antibody responses. Apart from DCs, it appears that intestinal epithelial cells also respond differently in terms of producing IgA mediators such as TGF-β and thymic stromal lymphopoietin (TSLP). Specifically, G− commensals induce higher production of TGF-β and TSLP as compared with G+ commensals (57). Further, higher frequencies of splenic TLR9+ mononuclear cells were detected in EcN + LGG colonized compared with the monocolonized EcN or LGG Gn piglets (32). TLR9 recognizes CpG DNA and LGG has a high GC percentage in its genomic DNA (58). Thus, we speculate that higher systemic TLR9 expression in EcN + LGG compared with EcN or LGG monoclonized piglets might be a contributing factor in enhancing immunoglobulin responses as reported in several earlier studies (59, 60).

One unanswered question is the involvement of total IgA levels in modulating immunopathology during microbial infections. Previous studies have shown the involvement of IgA in modulating inflammatory responses through modulating dendritic cells and regulatory T cell functions (61, 62). Further, secretory IgA-commensal complexes were shown to reduce inflammatory responses in intestinal epithelial cells (63). Thus, the role of secretory IgA in mitigating infection-induced inflammatory responses is intriguing and requires further investigation.

**Differential Effects of G+ versus G− Probiotics in Modulating Innate Immunity**

Probiotics may elicit their beneficial effects against pathogens through modulating innate immunity. A role for innate immunity in mediating host defenses against enteric diseases including RV infection has been elucidated in recent studies (64–67). Specifically, functions of dendritic cells are modulated by various probiotics. It appears that DC populations in the intestine can be modulated by intestinal commensals. This concept is supported by results of an investigation in which depletion of intestinal microbiota resulted in a reduction in DCs numbers in mucosal compartments as well as impaired resistance against influenza virus infection in mice (68). Additionally, G− commensal bacteria have higher immunostimulatory effects on DCs as compared with G+ commensals (69). For example, G− EcN increased frequencies of total plasmacytoid dendritic cells (pDCs) and activated pDCs, more than the G+ LGG probiotic in Gn piglets (32). Also, G− commensals were highly potent in the induction of maturation markers in DCs as compared with G+ commensals (53). Importantly, greater variation was observed among G+ commensals in modulating DC responses, compared with less variation among G− commensals (53). Thus, the distinct ability of G− bacteria such as EcN in modulating frequencies and functions of DCs may have beneficial impacts on induction of protective immunity against pathogens.

In our recently published study (32), we observed higher NK cytotoxic function and increased frequencies of pDCs in EcN colonized compared with LGG colonized or uncolonized piglets. The enhanced NK cell activity coincided with higher serum IL-12 levels in vivo in EcN colonized piglets (Figure 1) and also DC production of IL-12 in vitro (32). Similar to our studies, treatment of murine bone marrow-derived DCs (BMDCs) with EcN resulted in induction of IL-12 and IL-10 cytokines and induction of activation markers in BMDCs (70). In the same study, EcN administration reduced the development of allergen-specific Th2 responses (70). Thus, our results showed that NK cell function can be modulated by probiotics, and more importantly, only G− EcN but not G+ LGG, enhanced NK cell function. These findings were further corroborated by an earlier study in which the germ-free condition impaired the priming of NK cell function by microbial ligands (71). Further, the reduced NK cell function in microbiota-depleted mice was correlated with higher mouse cytomegalovirus titers post-viral challenge (71). A recent study (72) also showed the potential role of the outer membrane vesicles from EcN in induction of IL-22 cytokine responses. IL-22, along with IFN-λ, has been shown to effectively reduce RV replication in a mouse model (66). These results underscore not only the importance of intestinal commensals in regulating innate immunity against viral infections, but also the differential abilities of distinct known G+ or G− probiotics in regulating innate immune cells.

**Interactions between Commensals and Viruses That Alter Their Pathogenicity**

Direct interactions between viruses and bacteria are being increasingly investigated in recent studies (73–75). Specifically, direct binding of commensal microbiota is associated with either increased or decreased viral infections (76). The ability of mouse mammary tumor virus to bind with LPS was associated with increased virus pathogenicity (77). Similarly, poliovirus stability and viral attachment to target host cells were also enhanced by interaction with bacterial LPS or peptidoglycan (78). Further, EcN binds to HRV ex vivo but no such interaction was found between LGG and HRV (31). Also, in this study, prior treatment of epithelial cells with EcN, but not LGG, resulted in a significant reduction in the epithelial attachment of HRV in vitro. Further studies are required to elucidate the potential role of physical interactions between EcN and viruses in terms of altering the course of viral infection and pathogenicity. Expression of histo-blood group antigens (HBGA) was observed in some G− intestinal commensal bacteria (79) and certain of those HBGA-expressing bacteria were shown to enhance (73) enteric viral infection. Considering the direct interactions between the commensals and pathogens, any disturbances in microbiota compositions may lead to altered susceptibility or resistance to a particular enteric pathogen. Thus, further studies are required to assess whether any difference exists between G+ and G− bacteria in binding properties with various enteric viruses and the impact on the course of viral pathogenicity.

**CONCLUSION**

Comparison of the beneficial effects of G+ and G− probiotics and intestinal commensals indicated that the selected G− probiotic...
had higher beneficial effects in inducing protective immunity against enteric pathogens such as HRV as compared with the selected G+ probiotics in humans and animal models. In our simplified in vivo Gn piglet model system, it appears that the induced beneficial effects of G− EcN against HRV disease may be accomplished by the integrated interaction of DCs, NK cells, and immunoglobulins as well as direct binding of EcN to virus (Figure 1). Most of the initial studies showed that G− probiotics have higher immunostimulatory effects and better protective effects against HRV as compared with G+ probiotics. It remains to be determined whether these findings can be generalized to all G− commensals. Further, the potential ability of different G+ and G− probiotics to alter the composition as well as functionalities of the intestinal microbiota, and the consequences of these changes on microbial infections and vaccines is unclear. Identification of the essential components of probiotics that induce the beneficial effects against pathogens may also be useful in identifying probiotics or their products as novel adjuvants for vaccines.

**AUTHOR CONTRIBUTIONS**

All authors listed have made substantial direct contribution to the work.

**ACKNOWLEDGMENTS**

This work was supported by a grant from the NIAID, NIH (grant # R01 A1099451 to LJS, AV, and GR) and federal funds appropriated to the Ohio Agricultural Research and Development Center (OARDC) of The Ohio State University. The authors thank Dr. J. Hanson, R. Wood, and J. Oggi, J. Chepبنيno, and K. Scheuer for their technical assistance.

**REFERENCES**

1. Nicholson JK, Holmes E, Kinross J, Burcelin R, Gibson G, Jia W, et al. Host-gut microbiota metabolic interactions. *Science* (2012) 336:1262–7. doi:10.1126/science.1232813
2. Kamada N, Chen GY, Inohara N, Nunez G. Control of pathogens and pathogens by the gut microbiota. *Nat Immuno* (2013) 14:685–90. doi:10.1038/nl.2608
3. Kamada N, Nunez G. Role of the gut microbiota in the development and function of lymphoid cells. *J Immuno* (2013) 190:1389–95. doi:10.4049/jimmunol.1203100
4. Scholta PA, Oozeer R, Martin R, Amor KB, Knol J. The early settlers: intestines and the intestinal microbiota in early life. *Annu Rev Food Sci Technol* (2012) 3:345–47. doi:10.1146/annurev-food-022811-101120
5. Yatsunenko T, Rey FE, Manary MJ, Trehan I, Dominguez-Bello MG, Contreras M, et al. Human gut microbiome viewed across age and geography. *Nature* (2012) 486:222–7. doi:10.1038/nature11053
6. Arrieta MC, Stiensma LT, Amenyogbe N, Brown EM, Finlay B. The intestinal microbiome in early life: health and disease. *Front Immuno* (2014) 5:427. doi:10.3389/fimmu.2014.00427
7. Huda MN, Lewis Z, Kalanetra KM, Rashid M, Ahmad SM, Raqiq B, et al. Stool microbiota and vaccine responses of infants. *Pediatrics* (2014) 134:e362–72. doi:10.1542/peds.2013-3937
8. Huang JS, Bouvaros A, Lee JW, Díaz A, Davidson EJ. Efficacy of probiotic use in acute diarrhea in children: a meta-analysis. *Dig Dis Sci* (2002) 47:2625–34. doi:10.1023/A:1020501202369
9. Engelbrektson A, Korzenik JR, Pittler H, Sanders ME, Klaenhammer TR, Leyer G, et al. Probiotics to minimize the disruption of faecal microbiota in healthy subjects undergoing antibiotic therapy. *J Med Microbiol* (2009) 58:663–70. doi:10.1099/jmm.0.074615-0
10. Paglini C, Saced R, Banias G, Arsenaeu KO, Pizarro TT, Cominelli F. Probiotics promote gut health through stimulation of epithelial innate immunity. *Proc Natl Acad Sci U S A* (2010) 107:454–9. doi:10.1073/pnas.0910307107
11. Walker CLF, Rudan I, Liu L, Nair H, Theodoratou E, Bhutta ZA, et al. Effect of the continuous intake of probiotic-fermented milk containing Lactobacillus casei strain Shirota in fever in a mass outbreak of norovirus gastroenteritis and the faecal microflora in a health service facility for the aged. *Br J Nutr* (2011) 106:549–56. doi:10.1017/S000711451100064X
12. McFarland LV. Meta-analysis of probiotics for the prevention of antibiotic associated diarrhoea and the treatment of Clostridium difficile disease. *Am J Gastroenterol* (2006) 101:812–22. doi:10.1111/j.1572-0241.2006.08465.x
13. Sindhu KN, Sommyanarayanan TV, Paul A, Babji S, Ajampur SS, Priyadarshini S, et al. Immune response and intestinal permeability in children with acute gastroenteritis treated with Lactobacillus rhamnosus GG: a randomized, double-blind, placebo-controlled trial. *Clin Infect Dis* (2014) 58:1107–15. doi:10.1093/cid/ciu065
14. Sanders ME, Guarnier F, Guernt R, Holt PR, Quigley EM, Sartor RB, et al. An update on the use and investigation of probiotics in health and disease. *Gut* (2013) 62:787–96. doi:10.1136/gutjnl-2012-302504
15. Vlasova AN, Kandasamy S, Chattha KS, Rajashekar G, Saif LJ. Comparison of probiotic lactobacilli and bifidobacteria effects, immune responses and rotavirus infections and infection in different host species. *Vet Immunol Immunopathol* (2016) 172:72–84. doi:10.1016/j.vetimm.2016.01.003
16. Sanders ME, Guarnier F, Guernt R, Holt PR, Quigley EM, Sartor RB, et al. Probiotics or their products as novel adjuvants for vaccines. *Frontiers in Immunology* (2017) 8. doi:10.3389/fimmu.2017.00312
17. Chattha KS, Vlasova AN, Kandasamy S, Rajashekar G, Saif LJ. Divergent immunomodulating effects of probiotics on T cell responses to oral attenuated human rotavirus vaccine and virulent human rotavirus infection in a neonatal gnotobiotic piglet disease model. *J Immuno* (2013) 191:2144–56. doi:10.4049/jimmunol.1300678
18. Sanders ME, Guarnier F, Guernt R, Holt PR, Quigley EM, Sartor RB, et al. The probiotic strain Nissle 1917 (EcN) stops acute rotavirus diarrhoea in a neonatal gnotobiotic piglet disease model. *Pediatr Infect Dis J* (2002) 21:411–6. doi:10.1097/00006454-200205000-00012
19. Kaila M, Isolauri E, Saxelin M, Arvilmomi H, Vesikari T. Viable versus inactivated Lactobacillus strain GG in acute rotavirus diarrhoea. *Arch Dis Child* (1995) 72:51–3. doi:10.1136/adc.72.1.51
20. Guandalini S, Pensabene L, Zikri MA, Dias JA, Casali LG, Hoekstra H, et al. Lactobacillus GG administered in oral rehydration solution to children with acute diarrhoea: a multicenter European trial. *J Pediatr Gastroenterol Nutr* (2000) 30:54–60. doi:10.1097/00005176-200001000-00018
21. Barker SA, Sultana S, Fuchs GJ, Alam NH, Azim T, Brüssow H, et al. Lactobacillus paracasei strain ST11 has no effect on rotavirus but ameliorates the outcome of nonrotavirus diarrhoea in children from Bangladesh. *Pediatrics* (2005) 116:e221–8. doi:10.1542/peds.2013-3937
22. Kandasamy S, Rajashekar G, Chattha KS, Saif LJ. Comparison of probiotic lactobacilli and bifidobacteria effects, immune responses and rotavirus infections and infection in different host species. *Vet Immunol Immunopathol* (2016) 172:72–84. doi:10.1016/j.vetimm.2016.01.003
23. Kaila M, Isolauri E, Saxelin M, Arvilmomi H, Vesikari T. Viable versus inactivated Lactobacillus strain GG in acute rotavirus diarrhoea. *Arch Dis Child* (1995) 72:51–3. doi:10.1136/adc.72.1.51
24. Guandalini S, Pensabene L, Zikri MA, Dias JA, Casali LG, Hoekstra H, et al. Lactobacillus GG administered in oral rehydration solution to children with acute diarrhoea: a multicenter European trial. *J Pediatr Gastroenterol Nutr* (2000) 30:54–60. doi:10.1097/00005176-200001000-00018
25. Sarker SA, Sultana S, Fuchs GJ, Alam NH, Azim T, Brüssow H, et al. Lactobacillus paracasei strain ST11 has no effect on rotavirus but ameliorates the outcome of nonrotavirus diarrhoea in children from Bangladesh. *Pediatrics* (2005) 116:e221–8. doi:10.1542/peds.2004-2334
26. Henker J, Laass M, Blokhin BM, Bolbot YK, Maydannik VG, Elze M, et al. The probiotic Escherichia coli strain Nissle 1917 (EcN) stops acute
diarrhoea in infants and toddlers. *Eur J Pediatr* (2007) 166:311–8. doi:10.1007/s00431-006-0419-x

27. Lodinová–Žaadniková R, Tlaskalová–Hogenová H, Sonnenborn U. Local and serum antibody response in full-term and premature infants after artificial colonization of the intestine with *E. coli* strain Nissle 1917 (Mutafra*®*). *Pediatr Allergy Immunol* (1992) 3:43–8. doi:10.1111/j.1399-3038.1992.tb00026.x

28. Cukrowska B, Lodinová–Žádníková R, Enders C, Sonnenborn U, Schulze J, Tlaskalová–Hogenová H. Specific proliferative and antibody responses of premature infants to intestinal colonization with nonpathogenic probiotic *E. coli* strain Nissle 1917. *Scand J Immunol* (2002) 55:204–9. doi:10.1046/j.1365-3083.2002.01005.x

29. Lodinová–Žádníková R, Sonnenborn U. Effect of preventive administration of a nonpathogenic *Escherichia coli* strain on the colonization of the intestine with microbial pathogens in newborn infants. *Neonatology* (1997) 71:224–32. doi:10.1159/000244421

30. Spichalova A, Trebichavsky I, Rada V, Vlkova E, Sonnenborn U, Spichal I. Interference of *Bifidobacterium choerinum* or *Escherichia coli* Nissle 1917 with *Salmonella typhimurium* in gnotobiotic piglets correlates with cytokine patterns in blood and intestine. *Clin Exp Immunol* (2011) 146(1):232–9. doi:10.1111/j.1365-2249.2010.04283.x

31. Kandasamy S, Vlasova AN, Fischer D, Kumar A, Chatska KS, Rauf A, et al. Differential effects of *Escherichia coli* Nissle and *Lactobacillus rhamnosus* strain GG on human rotavirus binding, infection, and cell immunity. *J Immunol* (1996) 156:1780–9. doi:10.4049/jimmunol.1501705

32. Vlasova AN, Shao L, Kandasamy S, Fischer DD, Rauf A, Langel SN, et al. *Escherichia coli* Nissle 1917 protects gnotobiotic pigs against human rotavirus by modulating pDC and NK-cell responses. *Eur J Immunol* (2016) 46(10):4262–37. doi:10.1002/eji.201646498

33. Kreuzer S, Machnowska P, Almus J, Sieber M, Pieper R, Schmidt MF, et al. Feeding of the probiotic bacterium *Enterococcus faecium* NCIMB 10415 differentially affects shedding of enteric viruses in pigs. *Vet Res* (2012) 43:1. doi:10.1186/1297-9716-7-43

34. Schroeder B, Dunkner S, Barth S, Bauerfeind R, Gruber A, Deppenmeier S, et al. Preventive effects of the probiotic *Escherichia coli* strain Nissle 1917 on acute secretory diarrhea in a pig model of intestinal infection. *Dig Dis Sci* (2005) 51:724–31. doi:10.1016/j.deds.2005.06.018

35. Von Buenau R, Jaekel L, Schubotz E, Schwarz S, StroffTT, Krueger M. *Escherichia coli* strain Nissle 1917: significant reduction of neonatal calf diarrhea. *J Dairy Sci* (2005) 88:317–23. doi:10.3168/jds.S0022-0302(05)70260-4

36. Dagi C, Galdeano CM, Perdigon G. Gut immune stimulation by non pathogenic Gram (+) and Gram (−) bacteria. Comparison with a probiotic strain. *Cytokine* (2008) 41:223–31. doi:10.1016/j.cyto.2007.11.014

37. Ulrich N, Singh A, Drinkerburg U, Englehardt R, Seidler U, Hansen W, et al. Probiotic *Escherichia coli* Nissle 1917 inhibits leaky gut by enhancing mucosal integrity. *PLoS One* (2007) 2:e1308. doi:10.1371/journal.pone.0001308

38. Cross ML, Garner A, Teilab D, Fray LM. Patterns of cytokine induction by *Bifidobacterium breve* and *Lactobacillus rhamnosus* in gnotobiotic piglets with microbial pathogens in newborn infants. *Frontiers in Immunology* | www.frontiersin.org March 2017 Volume 8 Article 334

39. Hessle C, Andersson B, Wold AE. Gram-positive bacteria are potent inducers of monocytic interleukin-12 (IL-12) while Gram-negative bacteria preferentially stimulate IL-10 production. *Immunol Infect* (2000) 68:3581–6. doi:10.1016/S0043-139X(00)00127-9

40. Boyle RJ, Robins-Browne RM, Tang ML. Probiotic use in clinical practice: what are the risks? *Clin Exp Immunol* (2006) 144:304–11. doi:10.1111/j.1365-2249.2006.03096.x

41. Macpherson AJ, Uhr T. Induction of protective IgA by intestinal dendritic cells carrying commensal bacteria. *Science* (2004) 303:1662–5. doi:10.1126/science.1091334

42. Blaas S, Stieber-Gunkel M, Falk W, Obermeier F, Rogler G. CpG-oligodeoxynucleotides stimulate immunoglobulin A secretion in intestinal mucosal B cells. *Clin Exp Immunol* (2009) 155:534–40. doi:10.1111/j.1365-2249.2008.03855.x

43. Ouel M, Korkisch B, Moralez E, LeBlanc D, Bonnet M, Latarjet B. CpG oligodeoxynucleotides stimulate immunoglobulin A secretion in intestinal mucosal B cells. *Clin Exp Immunol* (2009) 155:534–40. doi:10.1111/j.1365-2249.2008.03855.x

44. Menard O, Butel M-J, Gaboriau-Routhiau V, Waligora-Dupriet A-J. Gnotobiotic mouse immune response induced by *Bifidobacterium* sp. strains isolated from infants. *Appl Environ Microbiol* (2008) 74:660–6. doi:10.1128/AEM.01261-07

45. Karlsson H, Hessel C, Rudin A. Innate immune responses of human neonatal cells to bacteria from the normal gastrointestinal flora. *Infect Immun* (2002) 70:6688–96. doi:10.1128/IAI.70.12.6688-6696.2002

46. Qi H, Denning TL, Soong L. Differential induction of interleukin-10 and interleukin-12 in dendritic cells by microbial toll-like receptor activators and skewing of T-cell cytokine profiles. *Infect Immun* (2003) 71:3337–42. doi:10.1128/IAI.71.6.3337-3342.2003
64. Vlasova AN, Chattha KS, Kandasamy S, Liu Z, Esseli M, Shao L, et al. Lactobacilli and bifidobacteria promote immune homeostasis by modulating innate immune responses to human rotavirus in neonatal gnotobiotic pigs. *PLoS One* (2013) 8:e76962. doi:10.1371/journal.pone.0076962

65. Zhang B, Chassaigne B, Shi Z, Uchiyama R, Zhang Z, Denning TL, et al. Prevention and cure of rotavirus infection via TLR5/NLRC4-mediated production of IL-22 and IL-18. *Science* (2014) 346:861–5. doi:10.1126/science.1257147

66. Hernández PP, Mahlakõiv T, Yang I, Schwierzeck V, Nguyen N, Guendel F, et al. Interferon-λ[lambda] and interleukin 22 act synergistically for the induction of interferon-stimulated genes and control of rotavirus infection. *Nat Immunol* (2015) 16:698–707. doi:10.1038/ni.3180

67. Shao L, Fischer DD, Kandasamy S, Rauf A, Langel SN, Wentworth DE, et al. Comparative in vitro and in vivo studies of porcine rotavirus G9P[13] and human rotavirus Wa G1P[8]. *J Virol* (2016) 90:142–51. doi:10.1128/JVI.02401-15

68. Ichinohe T, Pang IK, Kumamoto Y, Peaper DR, Ho JH, Murray TS, et al. Microbiota regulates immune defense against respiratory tract influenza A virus infection. *Proc Natl Acad Sci U S A* (2011) 108:5354–9. doi:10.1073/pnas.1019378108

69. Smits HH, Van Beelen AJ, Hessle C, Westland R, De Jong E, Soeteman E, et al. Commensal Gram-negative bacteria prime human dendritic cells for enhanced IL-23 and IL-27 expression and enhanced Th1 development. *Eur J Immunol* (2012) 42:2239–49. doi:10.1002/eji.201144210

70. Adam E, Delbrassinne L, Bouillot C, Reynders V, Mailleux AC, Muraille E, et al. Probiotic *Escherichia coli* Nissle 1917 activates DC and prevents house dust mite allergy through a TLR4-dependent pathway. *Eur J Immunol* (2010) 40:1995–2005. doi:10.1002/eji.200939913

71. Ganal SC, Sanos SL, Kallfass C, Oberle K, Johner C, Kirschning C, et al. Priming of natural killer cells by nonmucosal mononuclear phagocytes requires instructive signals from commensal microbiota. *Immunity* (2012) 37:171–86. doi:10.1016/j.immuni.2012.05.020

72. Fábrega MJ, Aguilera L, Giménez R, Varela E, Cañas MA, Antolin M, et al. Activation of immune and defense responses in the intestinal mucosa by outer membrane vesicles of commensal and probiotic *Escherichia coli* strains. *Front Microbiol* (2016) 7:705. doi:10.3389/fmicb.2016.00705

73. Jones MK, Watanabe M, Zhu S, Graves CL, Keyes LR, Grau KR, et al. Enteric bacteria promote human and mouse norovirus infection of B cells. *Science* (2014) 346:755–9. doi:10.1126/science.1257147

74. Karst SM. The influence of commensal bacteria on infection with enteric viruses. *Nat Rev Microbiol* (2016) 14:197–204. doi:10.1038/nrmicro.2015.25

75. Pfeiffer JK, Virgin HW. Transkingdom control of viral infection and immunity in the mammalian intestine. *Science* (2016) 351:aad5872. doi:10.1126/science.aad5872

76. Robinson CM, Pfeiffer JK. Viruses and the microbiota. *Annu Rev Virol* (2014) 1:55. doi:10.1146/annurev-virology-031413-085550

77. Kane M, Case LK, Kopaskie K, Kozlova A, Macdearmid C, Chervonsky AV, et al. Successful transmission of a retrovirus depends on the commensal microbiota. *Science* (2011) 334:245–9. doi:10.1126/science.1210718

78. Robinson CM, Jesudhasan PR, Pfeiffer JK. Bacterial lipopolysaccharide binding enhances virion stability and promotes environmental fitness of an enteric virus. *Cell Host Microbe* (2014) 15:36–46. doi:10.1016/j.chom.2013.12.004

79. Miura T, Sano D, Suenaga A, Yoshimura T, Fuzawa M, Nakagomi T, et al. Histo-blood group antigen-like substances of human enteric bacteria as specific adsorbents for human noroviruses. *J Virol* (2013) 87:9441–51. doi:10.1128/JVI.01060-13

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2017 Kandasamy, Vlasova, Fischer, Chattha, Shao, Kumar, Langel, Rauf, Huang, Rajashekar and Saif. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.